If the results of molecular target vectors operating on the Wnt/b-catenin cascade are not yet encouraging, the current literature reports drastic tumor volume reduction associated with good clinical outcomes after oral targeted therapy with BRAF and MEK inhibitors in PCPs [1,13,14,15]. The gene discussed is BRAF; the disease is neoplasm.